HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms

Core Viewpoint - HUTCHMED announces the renewal of the contract with the China National Healthcare Security Administration, ensuring that ORPATHYS® will remain on the National Reimbursement Drug List effective January 1, 2025, under the same terms as the previous agreement [1]. Group 1: Product Information - ORPATHYS® (savolitinib) is a selective MET tyrosine kinase inhibitor approved in China for treating non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations [2][5]. - The drug was first included in the National Reimbursement Drug List on March 1, 2023, highlighting the Chinese government's focus on improving drug affordability [3]. - ORPATHYS® is jointly developed by HUTCHMED and AstraZeneca, and it is the first selective MET inhibitor approved in China and included in the NRDL [5]. Group 2: Market Context - As of the end of 2023, approximately 1.33 billion people in China had basic medical insurance, covering around 95% of the population, which supports the market potential for ORPATHYS® [3]. - The NRDL is updated annually, and the inclusion of drugs is subject to a renewal process every two years, indicating a structured approach to drug reimbursement in China [3]. Group 3: Clinical Development - ORPATHYS® has shown clinical activity in advanced solid tumors and is currently under development for multiple tumor types, including lung, kidney, and gastric cancers [4][5].